Table 1 Study population baseline characteristics
Age (yrs) | Mean (SD) | 59 (6.6) |
Median (Range) | 58 (47-68) | |
Gender | Female | 11 (100%) |
Race | White | 11 (100%) |
Ethnicity | White | 11 (100%) |
Pathology (TNM Stage) | Tis | 4 (36.4%) |
T1a | 1 (9.1%) | |
T1b | 1 (9.1%) | |
T1c | 5 (45.5%) | |
N0 | 9 (81.8%) | |
NX | 2 (18.2%) | |
M0 | 4 (36.4%) | |
MX | 7 (63.6%) | |
Tumor Size (cm), Mean (SD) | 1.25 (0.60) | |
Median (Range) | 1.4 (0.2-2.2) | |
Eligible for Safety and Efficacy | Yes (received topical NG12-1) | 10 |
No (did not receive topical NG12-1) | 1 | |
Surgical Procedure | Lumpectomy | 9 |
Partial Mastectomy | 2 | |
Radiation Regimen | Standard Regimen without Boost | 2 |
Standard Regimen with Boost | 4 | |
Hypofractionated Regimen without Boost | 1 | |
Hypofractionated Regimen with Boost | 3 | |
Unknown (did not receive topical norepinephrine) | 1 |